Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis

Journal of Neuroimmunology

Volumn 263, Issue 1-2, 2013, Pages 159-161

  Baranowska Bik, Agnieszka ^a   Kochanowski, Jan ^b   Uchman, Dorota ^b   Wolinska Witort, Ewa ^c   Kalisz, Malgorzata ^c   Martynska, Lidia ^c   Baranowska, Boguslawa ^c   Bik, Wojciech ^c  

^a BIELANSKI HOSPITAL   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

IL 10; IL 6; Multiple sclerosis; PACAP; TNF ; VIP

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNOREGULATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION;

IL-10; IL-6; MULTIPLE SCLEROSIS; PACAP; TNFΑ; VIP;

ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84884819417     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.08.012     Document Type: Article

References (18)

1. Abad C., Waschek J.A. Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis. Curr. Pharm. Des. 2011, 17:1025-1035.
2. Abad C., Tan Y.V., Lopez R., Nobuta H., Dong H., Phan P., Feng J.M., Campagnoni A.T., Waschek J.A. Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19555-19560.
3. Andersen O., Fahrenkrug J., Wikkelsø C., Johansson B.B. VIP in cerebrospinal fluid of patients with multiple sclerosis. Peptides 1984, 5:435-437.
4. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
5. Fernandez-Martin A., Gonzalez-Rey E., Chorny A., Martin J., Pozo D., Ganea D., Delgado M. VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. Ann. N. Y. Acad. Sci. 2006, 1070:276-281.
6. high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 2005, 35:3343-3352.
7. Inoue A., Ohnishi M., Fukutomi C., Kanoh M., Miyauchi M., Takata T., Tsuchiya D., Nishio H. Protein kinase A-dependent substance P expression by pituitary adenylate cyclase-activating polypeptide in rat sensory neuronal cell line ND7/23 cells. J. Mol. Neurosci. 2012, 48:541-549.
8. Kato H., Ito A., Kawanokuchi J., Jin S., Mizuno T., Ojika K., Ueda R., Suzumura A. Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by supppresing the functions of antigen presenting cells. Mult. Scler. 2004, 10:651-659.
9. Milo R., Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun. Rev. 2010, 9:A387-A394.
10. Moody T.W., Ito T., Osefo N., Jensen R.T. VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18:61-67.
11. Passemard S., Sokolowska P., Schwendimann L., Gressens P. VIP-induced neuroprotection of the developing brain. Curr. Pharm. Des. 2011, 17:1036-1039.
12. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
13. Rostami A., Ciric B. Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J. Neurol. Sci 2013, (Apr 8.,pii: S0022-510X(13)00108-1). 10.1016/j.jns.2013.03.002.
14. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
15. Stromnes I.M., Cerretti L.M., Liggitt D., Harris R.A., Goverman J.M. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat. Med. 2008, 14:337-342.
16. Sun W., Hong J., Zang Y.C., Liu X., Zhang J.Z. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int. Immunol. 2006, 18:1691-1700.
17. Tan Y.V., Waschek J.A. Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis. ASN Neuro 2011, 3. (pii: e00065). 10.1042/AN20110024.
18. Tan Y.V., Abad C., Lopez R., Dong H., Liu S., Lee A., Gomariz R.P., Leceta J., Waschek J.A. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc. Nat. Acad. Sci. U. S. A. 2009, 106:2012-2017.